Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing phragmitis rhizoma extract as active ingredient for preventing, ameliorating, or treating disease attributed to side effect of anticancer agent

A technology of active ingredients and anticancer agents, applied in the direction of medical preparations containing active ingredients, drug combinations, plant/algae/fungus/moss ingredients, etc., can solve the problems of no public prevention, improvement or treatment, and achieve bone marrow restoration inhibitory effect

Inactive Publication Date: 2018-10-23
KOREA INST OF ORIENTAL MEDICINE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] As far as the technology related to the reed root extract is concerned, the preparation method of the reed root extract which has the function of enhancing immunity and anti-cancer disclosed in Korean Patent No. 1098875 is known, and the method disclosed in the Korean Patent No. 1151718 contains extract as an active ingredient for skin moisturizing, for the treatment of dermatitis or atopic dermatitis composition, but does not disclose the present invention containing reed rhizome extract as an active ingredient for the prevention, improvement or treatment of anti-cancer Composition of diseases caused by side effects of agents

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing phragmitis rhizoma extract as active ingredient for preventing, ameliorating, or treating disease attributed to side effect of anticancer agent
  • Composition containing phragmitis rhizoma extract as active ingredient for preventing, ameliorating, or treating disease attributed to side effect of anticancer agent
  • Composition containing phragmitis rhizoma extract as active ingredient for preventing, ameliorating, or treating disease attributed to side effect of anticancer agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Embodiment 1. Preparation of Reed Rhizome Extract

[0051]In order to prepare the active ingredient reed rhizome extract of the present invention, reed rhizome was purchased from Gwangmyeongdang Pharmaceutical Co., Ltd. (Ulsan, Korea). After pulverizing 100 g of the purchased reed rhizome, it was put into a round flask together with 2 L of water and mixed. Heat the constant temperature water tank (water bath) connected to the reflux extraction device attached with the cooling pipe, and repeat the extraction twice in total, each time for 2 hours. The extracted extract was filtered under reduced pressure using a paper filter paper (Whatman No. 2) and a vacuum pump (Vacuum pump, GAST Company). Using a rotary concentrator (Rotary evaporator, EYELA company), the filtered liquid phase extract was concentrated under reduced pressure, and the concentrated extract was freeze-dried, and then homogenized with a mortar to obtain reed rhizome extract things. It was packed in a se...

Embodiment 2

[0052] Example 2. Confirmation of hematopoietic toxicity of anticancer agents

[0053] In order to confirm the hematopoietic toxicity of anticancer agents currently used clinically, the growth and differentiation of hematopoietic stem cells in mouse bone marrow cells were confirmed by in vitro (ex vivo) and in vivo (in vivo) experiments. the resulting impact.

[0054] 1) Confirmation of hematopoietic toxicity effect of anticancer agent in mouse bone marrow cells (in vitro (ex vivo))

[0055] Bone marrow cells were isolated from mouse femurs. Afterwards, the above-mentioned bone marrow cells were cultured in MethoCult GF M3434 medium for 7-10 days to induce the growth of hematopoietic stem cells. The MethoCult GF M3434 medium contained docetaxel, doxorubicin, irinotecan, Paclitaxel and daunorubicin derived from mouse recombinant stem cell factor (recombinant murine stem cell factor, rm stem cell factor), rm IL-3, human derived recombinant IL-6 (recombinant human IL-6, rh IL- ...

Embodiment 3

[0060] Example 3. Confirmation of the effect of reed root extract on bone marrow toxicity induced by anticancer agents

[0061] In order to confirm whether the reed rhizome extract has the effect of alleviating the anticancer agent (15nM of docetaxel, 100nM of doxorubicin, 100μM of irinotecan, 50nM of paclitaxel and 100nM of daunorubicin) in bone marrow cells The effect of hematopoietic toxicity, combined treatment with 15nM docetaxel, 100nM doxorubicin, 100μM irinotecan, 50nM paclitaxel or 100nM daunorubicin and reed root extract confirmed the effect of alleviating myelotoxicity. Effect.

[0062] Specifically, bone marrow cells were isolated from the femurs of mice, and then MethoCult GF M3434 medium containing mouse-derived recombinant stem cell factor was treated with 15 nM of an anticancer agent such as docetaxel that induced hematopoietic toxicity of bone marrow cells. , rm IL-3, human-derived recombinant IL-6 and rh erythropoietin. Afterwards, 25 μg / ml, 50 μg / ml and 10...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition containing a Phragmitis Rhizoma extract as an active ingredient for preventing, ameliorating, or treating diseases attributed to side effects of anticancer agents. In the present invention, it was revealed that when mouse myelocytes were treated with a Phragmitis Rhizoma extract, hematopoietic stem cell colonies remarkably recovered from a reduced state caused by an anticancer agent and that an animal model in which bone marrow repression had been induced by the intraperitoneal injection of an anticancer agent remarkably recovered from the anticancer agent-induced bone marrow repression. Accordingly, the Phragmitis Rhizoma extract of the present invention can be usefully used in a composition for the prevention, amelioration, and treatment ofdiseases attributed by side effects of anticancer agents, and may increase the effect of an anticancer agent when administered as an anticancer agent aid in combination with the anticancer agent.

Description

technical field [0001] The present invention relates to a composition for preventing, improving or treating diseases caused by side effects of anticancer agents, containing Phragmitis Rhizoma extract as an active ingredient. Background technique [0002] Cancer occupies the first to second cause of death in Korea, and 30% of the dead in the 50s and 60s in Korea die from cancer. The most common treatments for this cancer are surgery, radiation therapy, and chemotherapy. Among them, various attempts have been made on the development of anticancer agents as chemotherapy, but so far it is still in a state where no real anticancer agent as a therapeutic agent has been developed, and adjuvant therapeutic agents only help to prolong short-term the extent of life. [0003] Anticancer agents used as chemotherapy intervene in the metabolic pathway of cancer cells, directly interact with DNA to block the process of DNA replication, transcription, and translation, or hinder the synthe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/899A23L33/105
CPCA23L2/02A23L2/52A61K36/899A23L33/105A61P7/06A61P43/00A23V2002/00A61K2236/331A61K2236/333A23L33/40
Inventor 金镇憙赵恩常金老洙方玉仙李裕珍金荣阿许恩娜
Owner KOREA INST OF ORIENTAL MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com